Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0004135 (
ATM
)
13,001
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Resistance to the chemotherapeutic drug 5'-azacytidine (5'-AZA) is a major obstacle in the treatment of patients with acute myeloid leukemia (AML). The
uridine-cytidine kinase 1
(
UCK1
) has an established role in activating 5'-AZA and its protein level is significantly downregulated in patients resistant to the drug. However, the underlying molecular mechanism for the reduced
UCK1
expression remains to be elucidated.
Methods:
Using mass spectrometry and molecular biochemistry analyses, we identified specific enzymes mediating
UCK1
degradation. Human AML cell lines and murine AML model were used to characterize the effects of these enzymes on 5'-AZA resistance.
Results:
We demonstrated that the ubiquitin E3 ligase KLHL2 interacted with
UCK1
and mediated its polyubiquitination at the K81 residue and degradation. We showed that deubiquitinase USP28 antagonized KLHL2-mediated polyubiquitylation of
UCK1
. We also provided evidence that
ATM
-mediated phosphorylation of USP28 resulted in its disassociation from KLHL2 and
UCK1
destabilization. Conversely,
UCK1
phosphorylation by 5'-AZA-activated
ATM
enhanced the KLHL2-
UCK1
complex formation. Importantly, silencing KLHL2 or USP28 overexpression not only inhibited AML cell proliferation but also sensitized AML cells to 5'-AZA-induced apoptosis
in vitro
and
in vivo
. These results were no longer observed in USP28-deficient cells.
Conclusions:
Our study revealed a novel mechanism by which the KLHL2/USP28/
ATM
axis mediates resistance of AML cells to 5'-AZA by regulating
UCK1
ubiquitination and phosphorylation. These results have direct clinical implications and provide a rationale for the combination drug treatment of AML patients.
...
PMID:Deubiquitinase USP28 inhibits ubiquitin ligase KLHL2-mediated uridine-cytidine kinase 1 degradation and confers sensitivity to 5'-azacytidine-resistant human leukemia cells. 3193 50